Kos Pharmaceuticals, Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kos Pharmaceuticals, Inc
Quite A Range: Adamas Ponders $10,000-$30,000 Price Tag For Gocovri
The US FDA approved the extended-release amantadine for levodopa-induced dyskinesia in Parkinson's disease. Adamas will finalize its pricing and begin selling the product later this year.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover J&J's and Medtronic's moves in a-fib, Abbott's acquisition of AMO, Northstar Neuroscience's demise and Invatec's European launch of its drug-eluting balloon. Plus a snapshot of ambulatory surgery in the US.
Back to Nature: Prescription Dietary Supplements Cash in on Cholesterol R&D Setbacks
Between big-name statins going generic and high-profile blow-ups like torcetrapib, Cordaptive and Vytorin, cholesterol drug development has been tough going. Some drug companies think the next big thing in lipid management is something different altogether: prescription-grade supplements. It may be just the thing for a risk-averse FDA.
What's the Difference? Sepracor's Xopenex Hit Hard by Coverage Cut
Xopenex reimbursement is being slashed by Medicare. The message: CMS wants proof of differentiation before it will pay more for line extensions and new formulations. That means trouble ahead for a lot of other products.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.